Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Astrocytoma, IDH-mutant (grades 2 to 4), drawn from the whole corpus: 9 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether vorasidenib should replace radiotherapy and chemotherapy or only defer them, and what to do at progression on it.
No IDH inhibitor has yet shown benefit in grade 3 or 4 IDH-mutant astrocytoma.
Cognitive decline after radiotherapy in people who live decades with the disease.
Temozolomide-induced hypermutation at recurrence has no specific treatment.
Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12 (INDIGO): first targeted therapy for low-grade glioma
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12
A milestone in how this cancer is treated.
PFS 27.
Mellinghoff and colleagues (NEJM): median progression-free survival 27.7 versus 11.1 months.